PRINCETON, N.J., March 7 /PRNewswire/ -- The Bull Market Report (http://www.bullmarket.com/), an online investment newsletter focused on long- term growth and income-generating stocks, announced that it has published an in-depth report on biotech companies focused on stem cell research, including Geron (NASDAQ:GERN), StemCells (NASDAQ:STEM), Aastrom Biosciences (NASDAQ:ASTM), and ViaCell (NASDAQ:VIAC).
All paid and trial subscribers to The Bull Market Report can now receive immediate access to the newsletter's exclusive daily reports. As a subscriber, you'll also gain access to our latest investment moves. Start your 14-day free trial today: https://www.bullmarket.com/subscribe/index.php?refer=BMR97 In its report, The Bull Market Report wrote: "Valuing these companies is quite difficult, as profitably can be as much as a decade away, if it can ever be obtained at all. Their potential as an investment, however, cannot be ignored. For the companies involved in embryonic stem cell research, government funding and ethical issues will remain a hindrance to research and growth. Additionally, the stem lines currently available to receive government funding are dwindling." In its coverage, The Bull Market Report looked at the following topics: -- Why is it important to differentiate companies doing stem cell
research with adult and umbilical cord stem cells versus those using
embryonic stem cells? -- What catalysts will drive these stocks in the near to medium term? -- Which companies look the most appealing as potential long-term
investments? -- What is the best strategy to employ for long-term investors interested
in investing in this niche of the biotech sector? About The Bull Market Report:
Launched in 1997, The Bull Market Report has a strong track record of creating wealth for its subscribers by providing sound, long-term investing advice. The Bull Market Report's Recommended List includes over 50 companies across all major industries, including Financials, Healthcare, Energy, Technology, and Retail, among others. The Bull Market Report is one of the oldest continuously published investment newsletters online.
NOTE: This release was published by Indie Research Advisors, LLC (CRD #131926), a registered investment advisor with the NASD and State of NJ. Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.
CONTACT: Marcie Martin, +1-888-278-5515 DATASOURCE: Indie Research Advisors, LLC CONTACT: Marcie Martin, Indie Research Advisors, LLC, +1-888-278-5515 Web site: http://www.bullmarket.com/
|